| Pulmonary thromboembolism. 2. New trends in prophylaxis and therapy. | |
| | |
MedLine Citation:
|
PMID: 7375411 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although low-dose heparin therapy is the technique most commonly used for prophylaxis of pulmonary thromboembolism, its usefulness is being questioned. Platelet deaggregation prophylaxis with either aspirin or dipyridamole, or both, apparently is a reasonable alternative, but further studies are needed. For treatment of pulmonary thromboembolism, continuous conventional-dose heparin therapy is the approach of choice. It has the highest therapeutic/toxic ratio and is the most effective technique for prevention of clot propagation. The patient's fibrinolytic network must be intact, however, if clot degradation is to occur. Fibrinolytic therapy with urokinase or streptokinase should be restricted to use in patients with massive pulmonary embolism in whom hemodynamics are unstable. Caval interruption and pulmonary embolectomy have lower benefit/risk ratios than do the medical alternatives and are rarely used for pulmonary thromboembolism. |
| | |
Authors:
|
J C Giudice; H J Komansky; J Kaufman |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Postgraduate medicine Volume: 67 ISSN: 0032-5481 ISO Abbreviation: Postgrad Med Publication Date: 1980 May |
Date Detail:
|
Created Date: 1980-07-22 Completed Date: 1980-07-22 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0401147 Medline TA: Postgrad Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 81-3, 86-9 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aspirin
/
therapeutic use Dipyridamole / therapeutic use Fibrinolytic Agents / therapeutic use Heparin / adverse effects, therapeutic use Humans Platelet Aggregation / drug effects Pulmonary Embolism / drug therapy*, prevention & control, surgery Vena Cava, Inferior / surgery |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 50-78-2/Aspirin; 58-32-2/Dipyridamole; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pulmonary thromboembolism. 1. Current concepts in pathogenesis and diagnosis.
Next Document: Pulmonary function in nonsmoking chronic alcoholics.